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1. Introduction
Common infectious diseases (CIDs) affecting the 
respiratory and gastrointestinal tract are a common 
problem for young children attending day-care centres 
or schools (Maldonado et al., 2012). These conditions are 
exacerbated by a general immaturity of the immune system 
and of respiratory and gastrointestinal tract functions 
(Maldonado et al., 2012). Evidence suggests that functional 
foods, derived from the fermentation of cow’s milk with 
probiotics, could be an effective dietary strategy to prevent 
infectious diseases in children, but data are still conflicting 
(Agostoni et al., 2007; Brunser et al., 1989; Campeotto 
et al., 2011; Merenstein et al., 2010; Mullié et al., 2004; 
Nagata et al., 2011; Thibault et al., 2004). Differences in 
the experimental design, study populations, and in bacterial 
strains used in the preparation of the fermented products 
could be responsible for these discrepancies (Agostoni 
et al., 2007; Brunser et al., 1989; Campeotto et al., 2011; 
Merenstein et al., 2010; Mullié et al., 2004; Nagata et al., 
2011; Thibault et al., 2004). Another limitation derives from 
the still largely undefined mechanisms of action elicited 
by fermented foods against infectious diseases (Shafi et 
al., 2014). The protective properties of fermented foods 
could be strain specific and dose-dependent. They could 
also derived from the activity of the probiotics (Hill et al., 
2014) and/or of food components produced during the 
fermentation process (Tamang et al., 2016). In a double-
blind, randomised, placebo-controlled trial, we found that 
fermented cow’s milk product with Lactobacillus paracasei 
CBA L74 (FM-CBAL74) efficiently protects schooled 
children against CIDs and that this protective effect is 
associated with a significant stimulation of both innate 
(α- and β-defensins and cathelicidin (LL-37)) and acquired 
(secretory immunoglobulin A) immunity (Nocerino et al., 
2017).
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Abstract
Cow’s milk fermented with Lactobacillus paracasei CBA L74 (FM-CBAL74) exerts a preventive effect against infectious 
diseases in children. We evaluated if this effect is at least in part related to a direct modulation of non-immune and immune 
defence mechanisms in human enterocytes. Human enterocytes (Caco-2) were stimulated for 48 h with FM-CBAL74 at 
different concentrations. Cell growth was assessed by colorimetric assay; cell differentiation (assessed by lactase expression), 
tight junction proteins (zonula occludens1 and occludin), mucin 2, and toll-like receptor (TRL) pathways were analysed 
by real-time PCR; innate immunity peptide synthesis, beta-defensin-2 (HBD-2) and cathelicidin (LL-37) were evaluated 
by ELISA. Mucus layer thickness was analysed by histochemistry. FMCBA L74 stimulated cell growth and differentiation, 
tight junction proteins and mucin 2 expression, and mucus layer thickness in a dose-dependent fashion. A significant 
stimulation of HBD-2 and LL-37 synthesis, associated with a modulation of TLR pathway, was also observed. FM-CBAL74 
regulates non-immune and immune defence mechanisms through a direct interaction with the enterocytes. These effects 
could be involved in the preventive action against infectious diseases demonstrated by this fermented product in children.
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It has been demonstrated that FM-CBAL74 elicits 
significant anti-inflammatory activities and protective 
effects against Salmonella thyphimurium in an animal 
model (Zagato et al., 2014). However, whether these effects 
are derived at least in part by a direct interaction with 
human enterocytes has not been defined. Thus, we designed 
this study with the aim to investigate the effect of a direct 
interaction between FM-CBAL74 and human enterocytes 
on the non-immune and immune defence mechanisms.
2. Materials and methods
Study products
The composition of the study products are reported in Table 
1. They were provided as a powder by Heinz Italia SpA 
(Latina, Italy), an affiliate of the Kraft Heinz Company, co-
headquartered in Pittsburgh, PA and Chicago, IL, USA. In 
all experiments we used the same product’s batch adopted 
in the RCT previously performed by our group (Nocerino 
et al., 2017). Briefly, FM-CBAL74 was prepared from skim 
milk fermented by L. paracasei CBA L74 (International 
Depository Accession Number LMG P-24778). The 
fermentation was started in the presence of 106 bacteria, 
reaching 5.9×1011 cfu/100 g after a 15 h incubation at 37 °C. 
After heating at 85 °C for 20 s in order to inactivate the 
living bacteria, the product was spray-dried. Thus, the final 
fermented milk powder contained only bacterial bodies 
and fermentation products and no living microorganisms.
Cell line
For all experiments, the human enterocytes cell line Caco-2 
was used (American Type Culture Collection, Teddington, 
UK). Cells were grown to confluence in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco, Berlin, Germany) 
supplemented with 20% foetal calf serum (Lonza, Visp, 
Switzerland), 1% L-glutamine (Lonza), 1% nonessential 
amino acids, and 1% penicillin/streptomycin (Lonza). Cells 
were cultured at 37 °C in a water-saturated atmosphere 
consisting of 95% air and 5% CO2, and the medium was 
changed every 2 days. All experiments were performed in 
triplicate and repeated twice.
Cell proliferation assay
Human enterocytes proliferation assays were assessed using 
MTT (the bromide salt of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium) (Sigma-Aldrich, Milan, Italy). 
Briefly, cells (104 cells/well) were seeded in 24-well plates 
(Corning, Inc., New York, NY, USA) with or without FM-
CBAL74 and non-fermented cow’s milk (NFM) at different 
doses (0.115-575 mg/ml) and then incubated for 48 h at 
37 °C in a 5% CO2 incubator. NFM served as the control. 
The cell viability was detected by adding 5 mg/ml of MTT 
solution followed by a 1 h incubation. The medium was 
then removed, and the converted dye was solubilised with 
acidic isopropanol (0.04-0.1 N HCl in absolute isopropanol). 
Absorbance was read at 570 nm using an Epoch Microplate 
Spectrophotometer (Bioteck, Winooski, VT, USA).
Innate immunity peptides synthesis
At full confluence (14 days), when a human enterocytes 
monolayer was obtained in six-well plates (Falcon, 
Heidelberg, Germany), cells were stimulated for 48 h with 
or without FM-CBAL74 and NFM at different doses. 
Afterward, the supernatants were harvested and stored at 
-80 °C for further use. Cells were used for RNA extraction 
to perform real-time PCR experiments. The concentration 
of β-defensin 2 (HBD-2) in the supernatants was measured 
using a commercially available ELISA kit specific for human 
HBD-2 (Phoenix Pharmaceuticals, Inc., Burlingame, CA, 
USA) with a detection limit of 15.6 pg/ml. Supernatant LL-
37 concentrations were determined with a human specific 
LL-37 ELISA kit (Hycult Biotech, Uden, the Netherlands) 
with a range of 0.1-100 ng/ml. The ELISAs were conducted 
according to the manufacturer’s recommendations.
Quantitative real-time PCR
Total cellular RNA was extracted from cells with TRIzol 
reagent (Gibco BRL, Paisley, UK). RNA (1 μg) was reverse 
transcribed at 37  °C in cDNA with a High-Capacity 
RNA-to-cDNA™ Kit (Life Technologies, Waltham, MA, 
USA) according to the manufacturer’s instructions. 
Complementary DNA (cDNA) was stored at -20 °C until 
Table 1. Composition of the study dietary products.
Value for 100 gr of product Fermented milk with Lactobacillus paracasei CBA L74 Non-fermented milk
Proteins, g 24.0 35.0
Carbohydrates, g 66.4 54.0
Fats, g 0.6 1.0
pH 6.6 6.6
L. paracasei CBA L74, cfu1 5.9×1011 -
1 Killed bacteria.
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use. Quantitative real-time PCR (qRT-PCR) analysis was 
performed to determine gene expression, and the results 
are reported in Table 2. After a hot start, the amplification 
protocol was 40 cycles of 30 s of denaturation at 95 °C, 30 s 
of annealing at 60 °C, and 1 min of elongation at 72 °C in a 
Light Cycler 7900HT (Applied Biosystems, Grand Island, 
NY, USA). The quantitative gene expression was calculated 
with the comparative Ct method and normalised against 
the Ct of glucuronidase (GUS) messenger as the reference 
gene, as previously reported by others (Wang et al., 2015).
Alcian Blue staining for mucus layer analysis
Human enterocytes were seeded onto polycarbonate 
membranes (0.4 μm pore size) from Transwell™ (Corning 
Inc., New York, NY, USA) at 37 °C in an atmosphere with 
95% humidity and 5% CO2. At full confluence (14 days), the 
cells were stimulated for 48 h with or without FM-CBAL74 
and NFM. A pair of membranes cultured under the same 
conditions were embedded immediately in an optimal 
cutting temperature compound (BioOptica, Milan, Italy) 
to avoid mucus damage during processing. 5 mm frozen 
sections of each sample were cut, and after rinsing in 3% 
acetic acid (Merck, Darmstadt, Germany), the cells were 
stained with 1% Alcian Blue (Merck) and oxidised in 1% 
periodic acid (Merck). Finally, sections were counterstained 
with Mayer’s haematoxylin and mounted with Aquamount 
(BDH, Poole, UK). Measurement of the mucus thickness 
was performed in the middle of the membrane using the 
ruler tool provided by the Zeiss Axio Observer/ApoTome 
(Carl Zeiss AG, Oberkochen, Germany).
Statistical analysis
The Kolmogorov-Smirnov test was used to determine 
whether variables were normally distributed. We used the 
t-test to evaluate differences among continuous variables. 
The level of significance for all statistical tests was 2-sided, 
P<0.05. All analyses were conducted in SPSS version 16.0 
for Windows (SPSS Inc., Chicago, IL, USA) and GraphPad 
Prism 5 (La Jolla, CA USA).
3. Results
Maturation and integrity of intestinal mucosa
The effect of the direct interaction between FM-CBAL74 
and human enterocytes on cell growth and differentiation 
is depicted in Figure 1. FM-CBAL74, but not NFM, 
induced a significant dose-dependent effect on cell growth 
and differentiation (measured by the result of lactase 
expression) with a maximum effective dose of 11.5 mg/
ml for both activities. The effect on human enterocytes 
monolayer permeability is reported in Figure 2. The positive 
modulation of intestinal permeability was confirmed by the 
up-regulation of tight junction (TJ) proteins expression, 
namely, zonula occludens 1 (ZO-1) and occludin, observed 
after stimulation with FM-CBAL74. No effect was observed 
in unstimulated cells (NT) or in enterocytes incubated with 
NFM. Again, the maximum effective dose was 11.5 mg/ml. 
The same dose of FM-CBAL74 was also able to up-regulate 
MUC2 expression (Figure 3). Accordingly, the enterocyte 
mucus layer thickness increased after stimulation with 
FM-CBAL74 (from 1±0.3 to 6±2 μm, P<0.05, as shown in 
Figure 4). No effects were observed in unstimulated cells 
or in enterocytes incubated with NFM.
Stimulation of innate immunity peptides synthesis
As shown in Figure 4, at the dose of 11.5 mg/ml, FM-
CBAL74 elicited a significant effect on HBD-2 and LL-37 
synthesis by human enterocytes. We also investigated the 
possible involvement of toll-like receptor (TRL) pathways 
in these effects. TLR2, transcriptional factor nuclear 
factor kappa B1 (Nf-kB1), and trefoil factor 3 (TFF3) 
expression was up-regulated in cells treated with FM-
CBAL74 compared to NFM and untreated cells (Figure 
5). In contrast, a down-regulation in pro-inflammatory 
TLR4 expression was observed in FM-CBAL74 stimulated 
cells (Figure 6).
Table 2. Primers for gene expression analysis.
Gene Forward sequence Reverse sequence GenBank
Lactase 5’-ACACGGTCGATTTCCTCTCT-3’ 5’-TGGGTTCTTCATGGTGGAGG-3’ NM_002299.3
ZO-1 5’-CCCCACTCTGAAAATGAGGA-3’ 5’-GGGAACAACATACAGTGACGC-3’ NM_001301025.1
Occludin 5’-ACAGACTACACAACTGGCGG-3’ 5’-TCATCAGCAGCAGCCATGTA-3’ NM_001205254.1
TRL2 5’-GGTCTTGGTGTTCATTATCTTC-3’ 5’-TCTCCCATTTCCGTCTTTTT-3’ NM_003264.3
TRL4 5’-CCGCTTCCTGGTCTTATCAT-3’ 5’-TCTGCTGCAACTCATTTCAT-3 NM_138554.3
Nf-kB1 5’-AAACACTGTGAGGATGGGATCTG-3’ 5’-CGAAGCCGACCACCATGT-3’ NM_003998.3
TFF3 5’-GTGCCAGCCAAGGACAG-3’ 5’-CGTTAAGACATCAGGCTCCAG-3’ NM_003226.3
MUC2 5’-CTCCGCATGAGTGTGAGT-3’ 5’-TAGCAGCCACACTTGTCTG-3’ NM_002457.4
GUS 5’-GAAAATATGTGGTTGGAGAGCTCATT-3’ 5’-CCGAGTGAAGATCCCCTTTTTA-3’ NM_000181.3
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Figure 1. Effect of direct interaction between Lactobacillus paracasei FM-CBAL74 and human enterocytes (caco-2 cells) on cell 
growth and differentiation. (A) Cell growth (expressed as percent of cell density) assessed by MTT assay. (B) Cell differentiation 
measured by lactase expression using RT-PCR. Data represent the mean (± standard deviation; represented by vertical bars) of 
two independent experiments, each performed in triplicate. Unstimulated cells (NT) were used as the reference sample. NFM = 
non-fermented cow’s milk; GUS = glucuronidase. * P<0.05 vs NFM or NT; ° P<0.05 vs NT.
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Figure 2. Effect of direct interaction between Lactobacillus 
paracasei FM-CBAL74 and human enterocytes (Caco-2 cells) on 
tight-junction proteins zonula occludens-1 (ZO-1) and occludin. 
Data represent the mean (± standard deviation); represented by 
vertical bars) of two independent experiments, each performed 
in triplicate. Unstimulated cells (NT) were used as the reference 
sample. NFM = non-fermented cow’s milk; GUS = glucuronidase. 
° P<0.05 vs NT; * P<0.05 vs NFM.
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Figure 3. Effect of direct interaction between Lactobacillus 
paracasei FM-CBAL74 and human enterocytes (Caco-2 cells) on 
mucus (MUC2) production. Data represent the mean (± standard 
deviation; represented by vertical bars) of two independent 
experiments, each performed in triplicate. Unstimulated cells 
(NT) were used as the reference sample. NFM = non-fermented 
cow’s milk; GUS = glucuronidase. ° P<0.05 vs NT; * P<0.05 
vs NFM.
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4. Discussion
The intestinal defence mechanisms against pathogens 
are numerous. Among these, the most important are the 
integrity of gut mucosa and immune factors (Berni Canani et 
al., 2011). The results of this study show that FM-CBAL74, 
through a direct interaction with human enterocytes, is 
able to regulate both these mechanisms. The activity on 
gut mucosa integrity is supported by the dose-dependent 
effects on cell growth and differentiation elicited by FM-
CBAL74. A significant stimulation of lactase expression 
was demonstrated. Lactase, a functional brush border 
enzyme, is a well-established biomarker of enterocytes 
differentiation (Rings et al., 1992). Lactase is frequently 
affected in acute gastroenteritis, and its diminished 
expression might be involved in post-gastroenteritis 
persistent diarrhoea and other gastrointestinal disorders 
(Solomons, 2002). The positive modulation of gut mucosa 
integrity by FM-CBAL74 is supported by the up-regulated 
expression of TJ proteins, which in turn are involved in 
the tuning of epithelial permeability. These results are 
in line with previous observations demonstrating a 
protective effect on epithelial barrier function elicited by 
fermentation products (Commane et al., 2005). Lastly, a 
significant increase of MUC2 expression and mucus layer 
thickness was also observed after stimulation of human 
enterocytes with FM-CBAL74. The mucus layer covers the 
entire gastrointestinal tract and represents the first line of 
defence against pathogens (Hansson, 2012). It has been 
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Figure 4. Effect of direct interaction between Lactobacillus 
paracasei FM-CBAL74 and human enterocytes (Caco-2 cells) 
on mucus thickness (μm). Data represent the mean (± standard 
deviation, represented by vertical bars) of two independent 
experiments, each performed in triplicate. ° P<0.05 vs non-
fermented cow’s milk (NFM).
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Figure 5. Effect of direct interaction between Lactobacillus 
paracasei FM-CBAL74 and human enterocytes (Caco-2 cells) 
on stimulation of innate immunity peptides synthesis. Beta-
defensin-2 (HBD-2) and cathelicidin (LL-37) production were 
assessed on cell supernatants by ELISA. Data represent the 
mean (± standard deviation; represented by vertical bars) of 
two independent experiments, each performed in triplicate. 
Unstimulated cells (NT) were used as the reference sample. 
NFM = non-fermented cow’s milk; GUS = glucuronidase. ° 
P<0.05 vs NT; * P<0.05 vs NFM.
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Figure 6. Effect of direct interaction between Lactobacillus 
paracasei FM-CBAL74 and human enterocytes (Caco-2 cells) 
on toll-like receptor (TRL) pathways. Data represent the 
mean (± standard deviation; represented by vertical bars) of 
two independent experiments, each performed in triplicate. 
Unstimulated cells (NT) were used as the reference sample. 
NFM = non-fermented cow’s milk; GUS = glucuronidase; TFF-3 
= trefoil factor 3; Nf-kB = nuclear factor kappa beta. ° P<0.05 
vs NT; * P<0.05 vs NFM.
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demonstrated that MUC2, a major mucus component, acts 
in a bi-directional way on innate immunity. It stimulates 
HBD-2 production (Cobo et al., 2015), and its expression 
could be regulated by LL-37 (Tai et al., 2008). Both innate 
immunity peptides resulted up-regulated after stimulation 
of human enterocytes with FM-CBAL74. Evidence suggests 
that TLRs pathway is important for many effects of 
probiotics in regulating the immune system (Yan and Polk, 
2011). Schlee et al. demonstrated that selected probiotics 
are able to increase the production of HBD-2 through 
the stimulation of TLR2 (Paolillo et al., 2009; Schlee et 
al., 2007). Other evidence has shown that L. paracasei 
stimulates TLR2 expression (Dogi et al., 2008). Our data 
show an increase in TLR2, NF-kB1 and TFF3 expression 
after FM-CBAL74 exposure. These results are in line with 
previous findings demonstrating that the NF-kB activation 
could lead to reinforcement of the epithelial barrier through 
release of anti-microbial peptides (i.e. HBD-2 and LL-
37) and through an increase in the production of TFF3 
trophic factor that can block human enterocytes apoptosis 
and enhance intestinal mucosa integrity (Ben-Neriah et 
al., 2007; Podolsky et al., 2009). Furthermore, we found a 
down-regulation of TLR4 expression, further supporting 
a potential anti-inflammatory activity of FM-CBAL74, as 
previously demonstrated in human dendritic cells (Zagato 
et al., 2014).
A major limitation of our study is that we did not investigate 
the specific FM-CBAL74 components that could be 
responsible for these effects. The effects of a fermented 
cow’s milk product could arise from several different 
probiotic components, including lipoteichoic acid (LTA), 
metabolites, nucleotides and peptides (Wells, 2011). It has 
been demonstrated that LTA from Gram-positive probiotics 
regulates TLR2-mediated response, triggering the MyD88-
dependent signalling pathway, which in turn is responsible 
for NF-κB activation and HBD-2 production (Buckley et 
al., 2006; Wehkamp et al., 2004). Concomitantly, peptides 
deriving from fermentation of cow’s milk proteins could 
act as modulators of non-immune and immune GI defence 
mechanisms (Hering et al., 2011; Marshall, 2004; Playford 
et al., 2000; Vinderola et al., 2007). A potential influence 
of different matrix on probiotics metabolism could not 
be excluded, as suggested by others (Burgain et al., 2014). 
Differences in bacterial strains used in the preparation of 
the fermented products could also influence the result, since 
it has been shown that the immune response to probiotics 
is generally regarded to be strain dependent and that there 
is a strain-dependent patterns of cytokine production, even 
among strains of the same species (Agostoni et al., 2007; 
Brunser et al., 1989; Campeotto et al., 2011; Dong et al., 
2012; Merenstein et al., 2010; Mullié et al., 2004; Nagata 
et al., 2011; Thibault et al., 2004).
Further studies are necessary to better characterise all FM-
CBAL74 components involved in the protective effects at 
gut level, as well as possible peculiarities of this particular 
product if compared with similar fermented products 
based on different probiotic strains. In conclusion, we 
have obtained data showing that FM-CBAL74, through a 
direct interaction with human enterocytes, up-regulates 
multiple non-immune and immune protective mechanisms 
for the intestinal mucosa. These beneficial effects could be 
involved, at least in part, in the preventive action against 
infectious diseases observed in children (Nocerino et al., 
2017).
Conflicts of interest
The authors have no conflict of interests that are directly 
relevant to the content of this paper, which remains their 
sole responsibility.
References
Agostoni, C., Goulet, O., Kolacek, S., Koletzko, B., Moreno, L., Puntis, 
J., Rigo, J., Shamir, R., Szajewska, H., Turck, D. and ESPGHAN 
Committee on Nutrition, 2007. Fermented infant formulae without 
live bacteria. Journal of Pediatric Gastroenterology and Nutrition 
44: 392-397.
Ben-Neriah, Y. and Schmidt-Supprian, M., 2007. Epithelial NF-kappa 
B maintains host gut microflora homeostasis. Nature Immunology 
8: 479-481.
Berni Canani, R., Buccigrossi, V. and Passariello, A., 2011. Mechanisms of 
action of zinc in acute diarrhea. Current Opinion in Gastroenterology 
27: 8-12.
Brunser, O., Araya, M., Espinoza, J., Guesry, P.R., Secretin, M.C. and 
Pacheco, I., 1989. Effect of an acidified milk on diarrhoea and 
the carrier state in infants of low socio-economic stratum. Acta 
Paediatrica Scandinavica 78: 259-264.
Buckley, J.M., Wang, J.H. and Redmond, H.P., 2006. Cellular 
reprogramming by Gram-positive bacterial components: a review. 
Journal of Leukocyte Biology 80: 731-774.
Burgain, J., Scher, J., Francius, G., Borges, F., Corgneau, M., Revol-
Junelles, A.M., Cailliez-Grimal, C. and Gaiani, C., 2014. Lactic acid 
bacteria in dairy food: surface characterization and interactions 
with food matrix components. Advances in Colloid and Interface 
Science 213: 21-35.
Campeotto, F., Suau, A., Kapel, N., Magne, F., Viallon, V., Ferraris, 
L., Waligora-Dupriet, A.J., Soulaines, P., Leroux, B., Kalach, N., 
Dupont, C. and Butel, M.J., 2011. A fermented formula in pre-term 
infants: clinical tolerance, gut microbiota, down-regulation of faecal 
calprotectin and up-regulation of faecal secretory IgA. British Journal 
of Nutrition 105: 1843-1851.
Cobo, E.R., Kissoon-Singh, V., Moreau, F. and Chadee, K., 2015. Colonic 
MUC2 mucin regulates the expression and antimicrobial activity of 
β-defensin 2. Mucosal Immunology 8: 1360-1372.
Commane, D.M., Shortt, C.T., Silvi, S., Cresci, A., Hughes, R.M. and 
Rowland, I.R., 2005. Effects of fermentation products of pro-and 
prebiotics on trans-epithelial electrical resistance in an in vitro model 
of the colon. Nutrition and Cancer 51: 102-109.
Please cite this article as 'in press'  Beneficial Microbes 
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
17
.0
03
8 
- M
on
da
y,
 O
ct
ob
er
 3
0,
 2
01
7 
8:
09
:3
4 
A
M
 - 
G
öt
eb
or
gs
 U
ni
ve
rs
ite
t I
P 
A
dd
re
ss
:1
30
.2
41
.1
6.
16
 
 Effects of fermented cow’s milk product with L. paracasei CBA L74
Beneficial Microbes ##(##) 7
Dogi, C.A., Galdeano, C.M. and Perdigón, G., 2008. Gut immune 
stimulation by non pathogenic Gram (+) and Gram (-) bacteria. 
Comparison with a probiotic strain. Cytokine 41: 223-231.
Dong, H., Rowland, I. and Yaqoob, P., 2012 Comparative effects of six 
probiotic strains on immune function in vitro. British Journal of 
Nutrition 108: 459-470.
Hansson, G.C., 2012. Role of mucus layers in gut infection and 
inflammation. Current Opinion in Microbiology 15: 57-62.
Hering, N.A., Andres, S., Fromm. A., Van Tol, E.A., Amasheh, M., 
Mankertz, J., Fromm, M., and Schulzke, J.D., 2011. Transforming 
growth factor-β, a whey protein component, strengthens the intestinal 
barrier by upregulating claudin-4 in HT-29/B6 cells. Journal of 
Nutrition 141: 783-789.
Hill, C., Guarner, F, Reid, G., Gibson, G.R., Merenstein, D.J., Pot, 
B., Morelli, L., Canani, B.R., Flint, H.J., Salminen, S., Calder, P.C. 
and Sanders, M.E., 2014. The International Scientific Association 
for Probiotics and Prebiotics consensus statement on the scope 
and appropriate use of the term probiotic. Nature Reviews: 
Gastroenterology and Hepatology 11: 506-514.
Maldonado, J., Cañabate, F., Sempere, L., Vela, F., Sánchez, A.R., 
Narbona, E., López-Huertas, E., Geerlings, A., Valero, A.D., Olivares, 
M. and Lara-Villoslada, F., 2012. Human milk probiotic Lactobacillus 
fermentum CECT5716 reduces the incidence of gastrointestinal and 
upper respiratory tract infections in infants. Journal of Pediatric 
Gastroenterology and Nutrition 54: 55-61.
Marshall, K., 2004. Therapeutic applications of whey protein. Alternative 
Medicine Review 9: 136-156.
Merenstein, D., Murphy, M., Fokar, A., Hernandez, R.K., Park, H., Nsouli, 
H., Sanders, M.E., Davis, B.A., Niborski, V., Tondu, F. and Shara, 
N.M., 2010. Use of a fermented dairy probiotic drink containing 
Lactobacillus casei (DN-114 001) to decrease the rate of illness in 
kids: the DRINK study. A patient-oriented, double-blind, cluster-
randomized, placebo-controlled, clinical trial. European Journal of 
Clinical Nutrition 64: 669-677.
Mullié, C., Yazourh, A., Thibault, H., Odou, M.F., Singer, E., Kalach, 
N., Kremp, O. and Romond, M.B., 2004. Increased poliovirus-
specific intestinal antibody response coincides with promotion 
of Bifidobacterium longum-infantis and Bifidobacterium breve in 
infants: a randomized, double-blind, placebo-controlled trial. Pediatric 
Research 56: 791-795.
Nagata, S., Asahara, T., Ohta, T., Yamada, T., Kond, S., Bian, L., Wang, C., 
Yamashiro, Y. and Nomoto, K., 2011. Effect of the continuous intake 
of probiotic-fermented milk containing Lactobacillus casei strain 
Shirota on fever in a mass outbreak of norovirus gastroenteritis and 
the faecal microflora in a health service facility for the aged. British 
Journal of Nutrition 106: 549-556.
Nocerino, R., Paparo, L., Terrin, G., Pezzella, V., Amoroso, A., Cosenza, 
L., Cecere, G., De Marco, G., Micillo, M., Albano, F., Nugnes, R., Ferri, 
P., Ciccarelli, G., Giaccio, G., Spadaro, R., Maddalena, Y., Canani, 
B.F. and Berni Canani, R., 2017. Cow’s milk and rice fermented with 
Lactobacillus paracasei CBA L74 prevent infectious diseases in 
children: a randomized controlled trial. Clinical Nutrition 36: 118-125.
Paolillo, R., Romano Carratelli, C., Sorrentino, S., Mazzola, N. and Rizzo, 
A., 2009. Immunomodulatory effects of Lactobacillus plantarum 
on human colon cancer cells. International Immunopharmacology 
9: 1265-1271.
Playford, R.J., Macdonald, C.E. and Johnson, W.S., 2000. Colostrum 
and milk-derived peptide growth factors for the treatment of 
gastrointestinal disorders. American Journal of Clinical Nutrition 
72: 5-14.
Podolsky, D.K., Gerken, G., Eyking, A. and Cario, E., 2009. Colitis-
associated variant of TLR2 causes impaired mucosal repair because 
of TFF3deficiency. Gastroenterology 137: 209-220.
Rings, E.H., De Boer, P.A., Moorman, A.F., Van Beers, E.H., Dekker, 
J., Montgomery, R.K., Grand, R.J. and Büller, H.A., 1992. Lactase 
gene expression during early development of rat small intestine. 
Gastroenterology 103: 1154-1161.
Schlee, M., Wehkamp, J., Altenhoefer, A., Oelschlaeger, T.A., Stange, 
E.F. and Fellermann, K., 2007. Induction of human beta-defensin 2 
by the probiotic Escherichia coli Nissle 1917 is mediated through 
flagellin. Infection and Immunity 75: 2399-2407.
Shafi, A., Farooq, U., Kashif, A., Mahgul, J., Farzana, S. and Amna, T., 
2014. Antidiarrheal effect of food fermented by various strains of 
Lactobacillus. Comprehensive Reviews in Food Science and Food 
Safety 13: 229-239.
Solomons, N.W., 2002. Fermentation, fermented foods and lactose 
intolerance. European Journal of Clinical Nutrition 5, Suppl. 4: S50-55.
Tai, E.K., Wong, H.P., Lam, E.K., Wu, W.K., Yu, L., Koo, M.W. and Cho, 
C.H., 2008. Cathelicidin stimulates colonic mucus synthesis by up-
regulating MUC1 and MUC2 expression through a mitogen-activated 
protein kinase pathway. Journal of Cell Biochemistry 104: 251-258.
Tamang, J.P., Shin, D.H., Jung, S.J. and Chae, S.W., 2016. Functional 
properties of microorganisms in fermented foods. Frontiers in 
Microbiology 7: 578.
Thibault, H., Aubert-Jacquin, C. and Goulet, O., 2004. Effects of 
long-term consumption of a fermented infant formula (with 
Bifidobacterium breve c50 and Streptococcus thermophilus 065) on 
acute diarrhea in healthy infants. Journal of Pediatric Gastroenterology 
and Nutrition 39: 147-152.
Vinderola, G., Matar, C., Palacios, J. and Perdigón, G., 2007. Mucosal 
immunomodulation by the non-bacterial fraction of milk fermented 
by Lactobacillus helveticus R389. International Journal of Food 
Microbiology 115: 180-186.
Wang, H., Yang, B., Geng, T., Li, B., Dai, P. and Chen, C., 2015. Tissue-
specific selection of optimal reference genes for expression analysis 
of anti-cancer drug-related genes in tumor samples using quantitative 
real-time RT-PCR. Experimental and Molecular Pathology 98: 375-381.
Wehkamp, J., Harder, J., Wehkamp, K., Wehkamp-von Meissner, B., 
Schlee, M., Enders, C., Sonnenborn, U., Nuding, S., Bengmark, S., 
Fellermann, K., Schröder, J.M. and Stange, E.F., 2004. NF-kappaB- 
and AP-1-mediated induction of human beta defensin-2 in intestinal 
epithelial cells by Escherichia coli Nissle1917: a novel effect of a 
probiotic bacterium. Infection and Immunity 72: 5750-5758.
Wells, J.M., 2011. Immunomodulatory mechanisms of lactobacilli. 
Microbial Cell Factories 10, Suppl. 1: S17.
Yan, F. and Polk, D.B., 2011. Probiotics and immune health. Current 
Opinion in Gastroenterology 27: 496-501.
Zagato, E., Mileti, E., Massimiliano, L., Fasano, F., Budelli, A., Penna, 
G. and Rescigno, M., 2014. Lactobacillus paracasei CBA L74 
metabolic products and fermented milk for infant formula have anti-
inflammatory activity on dendritic cells in vitro and protective effects 
against colitis and an enteric pathogen in vivo. PLoS ONE 9: e87615.
 Please cite this article as 'in press'
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
17
.0
03
8 
- M
on
da
y,
 O
ct
ob
er
 3
0,
 2
01
7 
8:
09
:3
4 
A
M
 - 
G
öt
eb
or
gs
 U
ni
ve
rs
ite
t I
P 
A
dd
re
ss
:1
30
.2
41
.1
6.
16
 
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
17
.0
03
8 
- M
on
da
y,
 O
ct
ob
er
 3
0,
 2
01
7 
8:
09
:3
4 
A
M
 - 
G
öt
eb
or
gs
 U
ni
ve
rs
ite
t I
P 
A
dd
re
ss
:1
30
.2
41
.1
6.
16
 
